"17th World Congress of Gastrointestinal Cancer17th World Congress of Gastrointestinal Cancer
July 1-4, 2015
The International Convention Center of Barcelona - Barcelona, Spain
Eric Wachter, PhD will present on July 2 at 10:30am and 4:55pm local time. [4:30am and 10:55am EDT]"
From PVCT .....
"Once the poster has been presented at the Congress [5:00am EDT?], Provectus will provide full details of its contents to the public."
Potential for early news Thursday?
"Significant adverse events were limited to injection site and photosensitivity reactions, and resolved
Omeros signs new licensing agreement, former USAID administrator joins board
Jun 18, 2015, 7:49am PDT
Puget Sound Business Journal
Seattle biopharmaceutical company Omeros hit another big milestone this week, announcing a major licensing deal with international pharmaceutical company Fagron.
Omeros (Nasdaq: OMER), which launched its first commercial product called Omidria in April, went public in 2009 and has 12 drugs in its pipeline including those in preclinical stages.
The company's OMS103, which was involved in the licensing deal with Fagron, is used during arthroscopic surgery. The deal will take OMS103 to market.
This most recent licensing deal, which is only for use within the U.S., Fagron will pay Omeros "a substantial majority share of the gross revenues generated from sales of OMS103 with Omeros also receiving a minimum revenue per vial sold," according to a press release.
Fagron will also pay Omeros up to $10 million in commercial milestones, some of which will be received by Omeros as revenue-share enhancement on early sales, the company said.
Omeros also announced this week that Dr. Rajiv Shah, the former administrator for the U.S. Agency for International Development (USAID) has been appointed to the company's board of directors.
"We are pleased to welcome Raj to our board – he brings an outstanding scientific background together with a proven track record of innovation in leading the world's premier development organization," said Dr. Gregory A. Demopulos, chairman and chief executive officer of Omeros, in a statement. "While at USAID, Raj creatively forged strategic partnerships with corporations and private capital to address some of the most pressing global problems, and he is a valuable addition to our team as we continue to expand our development and commercial activities."
That's a fair question, t_c16. His public profile is a significant cut above typical board members at microcap biotechs. I'd suggest his background is certainly as valuable as OMER Director Ray Aspiri's ...... "Chairman of the Board of Directors at Tempress Technologies, Inc., a research and development company specializing in high-pressure fluid dynamics for the oil and gas industry".
SEATTLE, June 17, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the company's board of directors.
From 2010 to 2015, Dr. Shah served as Administrator of USAID, the U.S. government agency responsible for administering civilian foreign aid. During his tenure, Dr. Shah led the efforts of nearly 10,000 staff in more than 70 countries around the world to advance USAID's mission of ending extreme poverty and promoting resilient, democratic societies.
"We are pleased to welcome Raj to our board - he brings an outstanding scientific background together with a proven track record of innovation in leading the world's premier development organization," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While at USAID, Raj creatively forged strategic partnerships with corporations and private capital to address some of the most pressing global problems, and he is a valuable addition to our team as we continue to expand our development and commercial activities."
"I am honored to join the Omeros board," said Dr. Shah. "With its strong leadership, Omeros is executing on its integrated strategy of commercial success with Omidria® to advance its deep and exciting pipeline of clinical and preclinical small-molecule and protein therapeutic programs. The strength of science and translational capabilities at Omeros are impressive, and I look forward to contributing to the future growth and direction of the company."
Note that once OMS103 is made available commercially by Fagron, it will be able to be used for all surgeries where inflammation and pain management are desired ....... open heart, joint replacements, spinal surgeries, accident injury treatments, etc. etc. etc.
Up 750,000 shares in the latest 2-week reporting period. Now just a hair below ten million shares ...... over 25% of the outstanding shares.
Meanwhile, institutions own over 50%.
Somebody is making a serious mistake and my money says it's the shorts.
......... "SOMEBODY" is going to develop ...... or be recognized as having ....... an ablative immunotherapy drug that is highly efficacious in treating solid tumors and:
1) It requires no assessment of patients' gene defects.
2) One off-the-shelf formulation can be used to treat all patients.
3) It has insignificant side effects.
4) It can be administered to all accessible tumors on an outpatient basis.
5) It has a low production cost and is easy to store and transport.
Mark my words: you can count on this happening.
You're too funny newt. PV-10 works on all solid tumors independent of gene mutations. No need to look for gene defects. No need to tailor the treatment to each patient. Simple. Effective. It'll gain ground.
Today's news is great but IMO it would be quite premature for OMER to announce specific partner info before they get the formal approval in July.
Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile -
SEATTLE, May 22, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is used during cataract surgery and other intraocular lens (IOL) replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and reduce postoperative eye pain. Cataract surgery and IOL replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015.
"For the quarter ended March 31, 2015, product revenue from the controlled launch of Omidria was $238,000"
About 500 doses of Omidria. Those might not all be uses. Some could be inventory at surgical centers.
4:30 PM EDT. Conference call and webcast.
Provectus Biopharmaceuticals' Abstract on Liver Cancer Accepted for Poster Presentation at European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer
Phase 1 Study Data to be Presented in Barcelona During WGI 2015, July 1-4, 2015
Thursday April 30, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc, a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), announced today that the European Society for Medical Oncology (ESMO) has accepted the Company's abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.
The conference runs July 1-4, 2015, and is being held at The International Convention Center of Barcelona, in Barcelona, Spain. The Company will post the presentation on its website at the time of the presentation.
The abstract, number P-116, will be available online on June 24, 2015. Provectus will provide more details about the presentation and conference as they become available.
The link is easy to get to ....... trustintelligence (+ (phonetic) daht kahm)
Click on "Trust Intelligence Discussion Forums"
Click on "BIOTECH: PROVECTUS (PVCT) + OMEROS (OMER) + more" toward bottom, under "Forum"
Click on "Omeros Corporation (OMER)"
Post #5 has the pros/cons
Alan Ross discusses this topic and provides links to articles in post #5 on the Omeros thread at TrustIntelligence daht kahm. It'll be interesting to see if that phonetic version of a link works. :-)
Prescient Investment Analysis
Disclosure: The author is long OMER.
Value, growth at reasonable price, event-driven
Omeros Corporation's Omidria Has Hallmarks Of Success
Apr. 16, 2015 2:31 PM ET
•There are multiple reasons that Omidria can be successful.
•Safety, ease of access, reduced stress on surgeons, and reimbursement are among them.
•The product's value appears substantial to investors.
Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma
Interim Data Expected When 50% of Events Achieved
Wednesday April 15, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The Company is seeking 225 patients and enrollment has begun at St. Luke's University Hospital and Health Network, Bethlehem, PA, the first study site to be opened, with additional sites to be added in the coming weeks and months.